hypertension

News

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.

News

The latest Apple Watch will include a just-approved health feature that will warn users if they show signs of chronic hypertension.

News

The race to market is on with Mineralys, as AstraZeneca showcases data for aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension.

News

Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.

News

George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.

News

Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.